| human | Q5 |
| P496 | ORCID iD | 0000-0001-9069-6512 |
| P4012 | Semantic Scholar author ID | 6635050 |
| P735 | given name | Santiago | Q13422956 |
| Santiago | Q13422956 | ||
| P106 | occupation | researcher | Q1650915 |
| Q90931002 | A Pilot Cross-Sectional Study to Investigate the Biomarker Potential of Phosphorylated Neurofilament-H and Immune Mediators of Disability in Patients With 5 Year Relapsing-Remitting Multiple Sclerosis |
| Q39209254 | A cross-sectional study on drug use in multiple system atrophy |
| Q43907139 | A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly |
| Q39264840 | A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients |
| Q36774986 | A multi-step pathway connecting short sleep duration to daytime somnolence, reduced attention, and poor academic performance: an exploratory cross-sectional study in teenagers |
| Q33767549 | A multifactorial study on nutritional status, binge eating and physical activity as main factors directly influencing body weight in Parkinson's disease |
| Q58870313 | A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson’s disease |
| Q50269844 | Actigraphic evaluation of motor fluctuations in patients with Parkinson's disease |
| Q43175529 | Activity-rest rhythm abnormalities in Parkinson's disease patients are related to dopaminergic therapy |
| Q51874888 | Addenbrooke's Cognitive Examination validation in Parkinson's disease. |
| Q42952828 | Adverse drug reactions to dopamine agonists: a comparative study in the French Pharmacovigilance Database |
| Q86092390 | Apomorphine for the treatment of refractory motor fluctuations in late stage Parkinson's disease: an old drug revisited |
| Q100457358 | Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations |
| Q92583617 | Associations Between Cardiovascular Events and Nonergot Dopamine Agonists in Parkinson's Disease |
| Q35944999 | Associations between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease |
| Q34417063 | Autosomal dominant cerebellar ataxias: a systematic review of clinical features |
| Q37634567 | Brief review: diurnal rhythms, obesity and educational achievement in South american cultures. |
| Q50778539 | Cardiac autonomic activity predicts dominance in verbal over spatial reasoning tasks: results from a preliminary study. |
| Q48247512 | Cerebroventricular administration of interferon-gamma modifies locomotor activity in the golden hamster |
| Q40381622 | Comparison of Olfactory Identification Patterns among Parkinson's Disease Patients from Different Countries. |
| Q100756516 | Correction to: Excessive buccal saliva in patients with Parkinson's disease of the French COPARK cohort |
| Q92586408 | Current Concepts in the Treatment of Multiple System Atrophy |
| Q43271401 | Decision-making in Parkinson's disease patients with and without pathological gambling |
| Q33917311 | Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease |
| Q38400380 | Design and development of a novel supportive care product for the treatment of sialorrhea in Parkinson's disease |
| Q52559152 | Disruption of ultradian and circadian rhythms of blood pressure in nondipper hypertensive patients. |
| Q42630468 | Do Parkinson's disease patients disclose their adverse events spontaneously? |
| Q43241338 | Does clinical intolerance to a diagnostic acute levodopa challenge differentiate multiple system atrophy from PD? |
| Q37798797 | Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinsonʼs Disease |
| Q64780571 | Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases |
| Q37889802 | Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France |
| Q38058214 | Drugs associated with restless legs syndrome: a case/noncase study in the French Pharmacovigilance Database |
| Q36142469 | Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine |
| Q44314293 | Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25-35 in the suprachiasmatic nuclei |
| Q64968139 | Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia |
| Q38005224 | Emerging analgesic drugs for Parkinson's disease |
| Q38078434 | Emerging drugs for autonomic dysfunction in Parkinson's disease |
| Q98936095 | Excessive buccal saliva in patients with Parkinson's disease of the French COPARK cohort |
| Q83452729 | Factors related to orthostatic hypotension in Parkinson's disease |
| Q41111540 | Falls in ambulatory non-demented patients with Parkinson's disease |
| Q48394513 | Gender differences in age-related increase of asleep blood pressure. |
| Q33447080 | Heart rate nonlinear dynamics during sudden hypoxia at 8230 m simulated altitude |
| Q79775475 | Infradian awake and asleep systolic and diastolic blood pressure rhythms in humans |
| Q87060075 | Investigational drugs for autonomic dysfunction in Parkinson's disease |
| Q48390798 | Irritability, psychomotor agitation and progressive insomnia induced by bilateral stimulation of the area surrounding the dorsal subthalamic nucleus (zona incerta) in Parkinson's disease patients |
| Q47615634 | L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey |
| Q38300388 | Management of constipation in Parkinson's disease |
| Q91574134 | Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders |
| Q64901060 | Movement Disorders in Autosomal Dominant Cerebellar Ataxias: A Systematic Review. |
| Q39006423 | New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study. |
| Q38570434 | New treatments for levodopa-induced motor complications |
| Q80490630 | Nocturnal hypertension defined by fixed cut-off limits is a better predictor of left ventricular hypertrophy than non-dipping |
| Q24187626 | Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson's disease |
| Q35028869 | Nonmotor symptoms groups in Parkinson's disease patients: results of a pilot, exploratory study |
| Q41652414 | Olfactory Dysfunction Evaluation Is Not Affected by Comorbid Depression in Parkinson's Disease |
| Q51483415 | Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson's disease: preliminary analysis from the French COPARK cohort. |
| Q48667620 | Parkinson disease: Serotonin reuptake inhibitors for depression in PD. |
| Q100435689 | Parkinson's Disease in the Era of a Novel Respiratory Virus Pandemic |
| Q34901847 | Parkinson's disease sleep scale, sleep logs, and actigraphy in the evaluation of sleep in parkinsonian patients |
| Q30244035 | Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration |
| Q38877254 | Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease |
| Q37776519 | Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease |
| Q34630735 | Pramipexole for the treatment of early Parkinson's disease |
| Q52564485 | Predictors of Cardiovascular Autonomic Neuropathy Onset and Progression in a Cohort of Type 1 Diabetic Patients. |
| Q48270196 | Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an 8-week treatment course |
| Q43232501 | Pregabalin-induced parkinsonism: a case report |
| Q92062226 | Prevalence and factors related to orthostatic syndromes in recently diagnosed, drug-naïve patients with Parkinson disease |
| Q85352505 | Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease |
| Q48076091 | Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease |
| Q67389951 | Prospective randomized 1-year follow-up comparison of bilateral subthalamotomy versus bilateral subthalamic stimulation and the combination of both in Parkinson's disease patients: a pilot study. |
| Q92584109 | Rating Scales for Pain in Parkinson's Disease: Critique and Recommendations |
| Q46316918 | Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease |
| Q38189113 | Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients |
| Q89848657 | Role of Astrocytic Dysfunction in the Pathogenesis of Parkinson's Disease Animal Models from a Molecular Signaling Perspective |
| Q64863210 | Rotigotine transdermal delivery for the treatment of Parkinson's disease |
| Q37982789 | Rotigotine transdermal patch for the treatment of Parkinson's Disease |
| Q37859776 | Safety of rasagiline for the treatment of Parkinson's disease |
| Q38543130 | Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms |
| Q36511561 | Sleep disordered breathing and daytime sleepiness are associated with poor academic performance in teenagers. A study using the Pediatric Daytime Sleepiness Scale (PDSS). |
| Q46422094 | Sleep habits, alertness, cortisol levels, and cardiac autonomic activity in short-distance bus drivers: differences between morning and afternoon shifts |
| Q92766122 | State-of-the-art pharmacotherapy for autonomic dysfunction in Parkinson's disease |
| Q41303725 | Subjective sleep dysfunction and insomnia symptoms in Parkinson's disease: Insights from a cross-sectional evaluation of the French CoPark cohort |
| Q33607256 | The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease |
| Q100522431 | The Parkinson's disease pain classification system (PDPCS): results from an international mechanism-based classification approach |
| Q34512544 | The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease |
| Q98774928 | Therapeutic strategies for Parkinson's disease: promising agents in early clinical development |
| Q35847512 | Trends in inpatient antiparkinson drug use in the USA, 2001-2012. |
| Q38199744 | Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant |
| Q64785268 | Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review |
| Q92530214 | Utilization Patterns of Amantadine in Parkinson's Disease Patients Enrolled in the French COPARK Study |
| Q51929370 | Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's disease. |
| Q83193503 | Validation of a new scale to assess olfactory dysfunction in patients with Parkinson's disease |
| Q48440512 | Validation of the sleep related items of the Non-motor Symptoms Questionnaire for Parkinson's disease (NMSQuest). |
Search more.